Quick Search

 

 


 

 

Home > Protocol Summaries: Compounds > GSK1711805 > Protocol Summary for 111684

Protocol Summary for 111684

Protocol Summary
Protocol Id: 111684
Secondary Ids:
  • N/A
Title: Analysis of expression of antigens in bone marrow samples from volunteering donors.
Phase: n\a
Acronym:
FDA Regulated Intervention?: No
Section 801 Clinical Trial?:
Delayed Posting:
IND/IDE Protocol?: no
Study Type: Observational
Oversight Authority:
  • Belgium: Federal Agency for Medicinal Products and Health Products
Collaborators:
  • N/A
Brief Summary: Antigen expression levels in bone marrow from volunteering donors will be analyzed. The results of this analysis will be used to establish a clinical test to identify cancer patients who could qualify to receive an investigational treatment being developed by GlaxoSmithKline.
Detailed Description:
Record Verification Date: January 2009
Status: Completed
Why Study Stopped:
Study Start Date: July 2008
Study Completion Date: January 2009
Study Completion Date Type: Actual
Primary Completion Date: January 2009
Primary Completion Date Type: Actual
Study Design:
Time Perspective:
Biospecimen Retention:
Biospecimen Description:
Primary Outcomes:
  • Levels of antigen expression in bone marrow no At the time of analysis
Secondary Outcomes:
  • Not applicable
Conditions:
  • Cancer
Keywords:
  • bone marrow
  • volunteers
  • antigen expression
Study Population:
Sampling Method:
Eligibility Criteria: Click to view inclusion/exclusion criteria
Gender: Both
Minimum Age: 18 Year
Maximum Age:
Enrollment: 48
Enrollment Type: Actual
Healthy Volunteers?: yes
Central Contact: US GSK Clinical Trials Call Center
Central Contact Phone: 877-379-3718
Central Contact Email: GSKClinicalSupportHD@gsk.com
Backup Central Contact: EU GSK Clinical Trials Call Center
Backup Central Contact Phone: +44 (0) 20 8990 4466
Backup Central Contact Email: GSKClinicalSupportHD@gsk.com
Overall Study Official: GSK Clinical Trials
Overall Study Official Affiliation: GlaxoSmithKline
Overall Study Official Role: Study Director
Responsible Party Name/Official Title: Cheri Hudson; Clinical Disclosure Advisor
Responsible Party Organization: GSK Clinical Disclosure
Location and Contact Information: Click to view location information